Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity

Martina Wirtz1, Alexander Schmidt1*, Margret Schottelius1, Stephanie Robu1, Thomas Günther1, Markus Schwaiger2 and Hans-Jürgen Wester1

Abstract

**Background:** Several radiolabeled prostate-specific membrane antigen (PSMA) inhibitors based on the lysine-urea-glutamate (KuE) motif as the pharmacophore proved to be suitable tools for PET/SPECT imaging of the PSMA expression in prostate cancer patients. PSMA I&T, a theranostic tracer developed in our group, was optimized through alteration of the peptidic structure in order to increase the affinity to PSMA and internalization in PSMA-expressing tumor cells. However, further structural modifications held promise to improve the pharmacokinetic profile.

**Results:** Among the investigated compounds 1–9, the PSMA inhibitors 5 and 6 showed the highest PSMA affinity (lowest IC50 values) after the introduction of a naphthylalanine modification. The affinity was up to three times higher compared to the reference PSMA I&T. Extended aromatic systems such as the biphenylalanine residue in 4 impaired the interaction with the lipophilic binding pocket of PSMA, resulting in a tenfold lower affinity. The IC50 of DOTAGA-conjugated 10 was slightly increased compared to the acetylated analog; however, efficient PSMA-mediated internalization and 80% plasma protein binding of 68Ga-10 resulted in effective tumor targeting and low uptake in non-target tissues of LNCaP tumor-bearing CD-1 nu/nu mice at 1 h p.i., as determined by small-animal PET imaging and biodistribution studies. For prolonged tumor retention, the plasma protein binding was increased by insertion of 4-iodo-D-phenylalanine resulting in 97% plasma protein binding and 16.1 ± 2.5% ID/g tumor uptake of 177Lu-11 at 24 h p.i.

**Conclusions:** Higher lipophilicity of the novel PSMA ligands 10 and 11 proved to be beneficial in terms of affinity and internalization and resulted in higher tumor uptake compared to the parent compound. Additional combination with para-iodo-phenylalanine in the spacer of ligand 11 elevated the plasma protein binding and enabled sustained tumor accumulation over 24 h, increasing the tumor uptake almost fourfold compared to 177Lu-PSMA I&T. However, high renal uptake remains a drawback and further studies are necessary to elucidate the responsible mechanism behind it.

**Keywords:** PSMA, Prostate cancer, Radiopharmaceutical, PET, Endoradiotherapy

**Background**

Due to the high overexpression in the majority of prostate cancers and low expression density in healthy tissues, the cell surface-bound zinc metalloprotease prostate-specific membrane antigen (PSMA) has attracted attention as a target for diagnosis and therapy of prostate cancer [1–3].

Recently, targeting of PSMA has been described for a variety of small molecule inhibitors and antibodies, and ([[(S)-5-amino-1-carboxypentyl]carbamoyl]-L-glutamic acid (L-lysine-urea-L-glutamate; KuE) was found to be a highly potent binding motif in small molecules for the active center of PSMA [4–12]. To improve the interaction of PSMA inhibitors with the enzyme, a lipophilic binding pocket (arene-binding site) was described in a distinct distance from the active center of PSMA, which induces an up to 60-fold increase in affinity for PSMA inhibitors containing...
a dinitrophenyl group to bind this lipophilic pocket [13]. The PSMA inhibitor $^{68}$Ga-HBED-CC-Ahx-KuE (PSMA-11) was described for addressing both of these binding pockets [14]. This PSMA inhibitor successfully demonstrated the diagnostic potential of PSMA-targeted molecular imaging with PET [15, 16]. Prostate cancer and its metastases were also visualized and treated with $^{68}$Ga-PSMA I&T PET [17, 18] and $^{177}$Lu-PSMA I&T radioligand therapy [17, 19–21], respectively. Compared to phenylalanine (f) in DOTAGA-fk(Sub-KuE), a first-generation PSMA inhibitor developed by our group [22], an increased interaction of iodo-tyrosine (I-y) in DOTAGA-(I-y)fk(Sub-KuE) (PSMA I&T—for imaging and therapy) [17] with this lipophilic pocket most likely explains the higher PSMA affinity and increased internalization of PSMA I&T into PSMA-expressing cells [17]. In addition, $^{111}$In-PSMA I&T was successfully utilized for intraoperative detection of lymph node metastases in the context of radio-guided surgery, which supported the development of the $^{99m}$Tc-based analog PSMA I&S [7, 23, 24].

The objective of this work was to investigate the influence of lipophilic amino acid substitutions in the linker of a series of acetylated PSMA inhibitors (Fig. 1) based on PSMA I&T to further improve the in vivo characteristics of this class of PSMA inhibitors. Compounds 1–9 were designed to bind the active center of PSMA by interaction with the KuE motif, which was conjugated via a suberic acid spacer to a three-amino acid peptide motif (for interaction with the lipophilic binding pocket of PSMA). In this exploratory part of the study, the DOTAGA chelator (1,4,7,10-tetraazacyclododecane-1(-glutaric acid)-4,7,10-triacetic acid) in PSMA I&T was substituted by an acetyl moiety, which is entirely sufficient to disclose relevant structure-activity relationships determined by the spacer geometry. Based on the PSMA ligand Ac-Y-2-Nal-K(Sub-KuE), which revealed the highest affinity to PSMA in this series, the DOTAGA-conjugated PSMA inhibitor DOTAGA-y-2-nal-k(Sub-KuE) was synthesized from D-amino acids in the spacer to increase metabolic stability in vivo and was preclinically evaluated according to previous investigations by our group [22].

In the literature, para-halogenated aromatic systems conjugated to the N-terminal amino group of KuE seem favorable in terms of PSMA affinity [25] and PSMA inhibitors containing a para-iodo-benzoic acid derivative as albumin binder demonstrated an increased tumor uptake in vivo [26, 27]. In addition, para-halogenated aromatic systems are reported to increase plasma protein binding [28–30], and a reduced tracer uptake in the kidneys was reported for radiopharmaceuticals modified with an albumin-binding entity [31]. Therefore, we designed several derivatives of the known PSMA inhibitor PSMA I&T in terms of structural modification of the spacer unit with lipophilic moieties, and additionally, we introduced a para-halogenated aromatic residue, para-iodo-phenylalanine (I-f), into the linker between the binding motif and the spacer unit. Subsequently, all PSMA ligands were evaluated regarding PSMA affinity, and the most promising structure 6 was further used to develop the PSMA inhibitors 10 and 11 (Fig. 2). These two ligands were radiolabeled with $^{68}$Ga and $^{177}$Lu and comparatively evaluated with particular respect

![Chemical structures of the acetylated PSMA inhibitors 1–9](image-url)
to internalization in LNCaP cells, lipophilicity, plasma protein binding, and albumin binding. In order to assess the influence of the structural modifications in vivo, both ligands were evaluated in micro-PET imaging and biodistribution studies and compared to PSMA I&T.

Results and discussion

Synthesis

The PSMA inhibitors 1–9 (Fig. 1) were synthesized in a combined solution and solid-phase synthesis strategy. The acetylated three-amino acid peptides (amino acid spacer in Fig. 1) were assembled using Fmoc-protocol solid-phase peptide synthesis starting from approximately 100 mg TCP resin. Acidic cleavage from the resin and precipitation in diethyl ether yielded the peptides in medium to high yields and purity. Acetyl ester formation at the unprotected side chain hydroxyl group of 8 and 9 necessitated an additional “deprotection step,” which was achieved by alkaline hydrolysis using methanol/water/saturated NaHCO₃ (2/1/1) in almost quantitative yields. The reaction of the crude peptides with NHS-Sub-(O₄Bu)KuE(O₄Bu)₂ was performed according to a literature procedure [22]. After removal of the solvent and acidic deprotection, the PSMA inhibitors were purified using RP-HPLC.

The DOTAGA-conjugated inhibitor 10 was synthesized from the DOTAGA-γ-nal-k peptide and PfpO-Sub-(O₄Bu)KuE(O₄Bu)₂ yielding the PSMA inhibitor after tBu deprotection and HPLC purification. The NHS ester of suberic acid is commercially available; however, the PfpO ester (Sub(OPfp)₂) was synthesized in 68% yield from affordable reagents resulting in a less hydrolysis-prone building block.

Hydrolytic stability was especially important for the synthesis of PSMA inhibitor 11. To address plasma proteins, a PSMA inhibitor with a halogenated aromatic moiety (4-iodo-D-phenylalanine; I-f) was developed on the basis of 10. Substitution of the suberic acid spacer with glutaric acid-(I-f) resulted in DOTAGA-γ-nal-k(Glut-(I-f)-KuE) (11). For the synthesis of 11, PfpO-Glut-(I-f)-(O₄Bu)KuE(O₄Bu)₂ was synthesized in solution from (O₄Bu)KuE(O₄Bu)₂, Fmoc-D-iodo-phenylalanine, and the bis-pentafluorophenylester of glutaric acid (Glut(OPfp)₂) and was purified using RP-HPLC. Glut(OPfp)₂ was prepared from glutaric acid using pyridine and pentafluorophenol in 87% yield after flash chromatography. Synthesis yields of PSMA inhibitors 1–11 are summarized in Additional file 1: Table S1.

Affinity to PSMA

The effect of the lipophilic (aromatic) modifications in the spacer unit of the acetylated PSMA inhibitors 1–9 on the IC₅₀ to PSMA was determined in a competitive binding assay on PSMA-expressing LNCaP cells. (((S)-1-carboxy-5-(4-[[13]iodo-benzamido]pentyl)carbamoyl)-L-glutamic acid (¹²⁵I-IBA)) in a concentration of 0.2 nM was used as radioligand [22]. The means of three independent measures are summarized in Table 1. The acetylated L-derivative, Ac-YFK(Sub-KuE) (1), was included to
nine) and 7 were investigated with inhibitors with PSMA I&T [17], iodo-tyrosine-like substituents with a similar biphenyl residue demonstrated the highest Ki among the tested set of ligands [34]. Yet, in a recent investigation, a PSMA inhibitor was comparable to metallated 10 being in the low nanomolar range. Thus, substitution of suberic acid in inhibitor 10 by glutaric acid-(iodo-phenylalanine) in inhibitor 11 does not increase the affinity to PSMA as reported previously for PSMA inhibitors with aromatic moieties conjugated to the KuE motif [28].

### Table 1 Affinities (IC50 values) of the PSMA inhibitors in this study as determined in a competitive binding assay on LNCaP cells (150,000 cells/well; 4 °C, 1 h, c125I-IBA = 0.2 nM as the reference ligand). Data are expressed as mean ± SD (n = 3).

| PSMA inhibitor | PSMA inhibitors (amino acid code) | IC50  |
|----------------|----------------------------------|-------|
| 1              | Ac-YFK(Sub-KuE)                   | 15.0 ± 1.3 |
| 2              | Ac-WK(Sub-KuE)                    | 6.8 ± 3.3  |
| 3              | Ac-Y-(Benzoathienyl-A)(Sub-KuE)   | 10.2 ± 4.0 |
| 4              | Ac-Y-(Biphenyl-A)(Sub-KuE)       | 1394 ± 1170 |
| 5              | Ac-Y-1-Nal-K(Sub-KuE)            | 4.3 ± 0.9  |
| 6              | Ac-Y-2-Nal-K(Sub-KuE)            | 3.9 ± 1.7  |
| 7              | Ac-Y-(4-NO2-F)(K)Sub-KuE)        | 7.4 ± 0.5  |
| 8              | Ac-Y(3,5-di-I-Y)K(Sub-KuE)       | 3.8 ± 0.6  |
| 9              | Ac-Y(3-CH3-Y)K(Sub-KuE)          | 7.2 ± 0.9  |
| PSMA I&T       | DOTAGA-(I-y)fk(Sub-KuE)          | 10.2 ± 3.5*|
| natGa-PSMA I&T | natGa-DOTAGA-(I-y)fk(Sub-KuE)     | 9.3 ± 3.3*|
| natLu-PSMA I&T | natLu-DOTAGA-(I-y)fk(Sub-KuE)     | 7.9 ± 2.4*|
| 10             | DOTAGA-y-2-nal-k(Sub-KuE)        | 8.5 ± 2.5  |
| natGa-10       | natGa-DOTAGA-y-2-nal-k(Sub-KuE)  | 9.8 ± 3.2  |
| natLu-10       | natLu-DOTAGA-y-2-nal-k(Sub-KuE)  | 2.1 ± 0.8  |
| 11             | DOTAGA-y-2-nal-k((I-f)-Glut-KuE) | 4.6 ± 0.9  |
| natGa-11       | natGa-DOTAGA-y-2-nal-k((I-f)-Glut-KuE) | 9.3 ± 2.9 |
| natLu-11       | natLu-DOTAGA-y-2-nal-k((I-f)-Glut-KuE) | 6.1 ± 1.6 |

*Data were taken from Ref. [17].

### Internalization and cell binding

To determine an effect on the cell binding and internalization of radiolabeled 10 and 11 (Additional file 1: Figure S1), LNCaP cells (125,000/well) were incubated with 0.2 nM 68Ga or 0.5 nM 177Lu-10 or 177Lu-11, respectively, up to 1 h at 37 °C as described in the literature [17, 22]. A 2-(phosphonomethyl)pentane-1,5-dioic acid (PMPA) wash step (10 μM, 10 min, 4 °C) was conducted to differentiate between specifically membrane-bound (<3% of applied dose) and internalized activity. Nonspecific binding, determined by co-incubation with 10 μM PMPA, was below 1% of the applied dose. To compensate for differences in cell count and viability, the external reference 125I-IBA was always assayed in parallel, and the binding data in Table 2 are given as percentage of the external reference. As expected from the affinity data, the internalization of 177Lu-10 was comparable to 177Lu-PSMA I&T. Interestingly, the cell binding and internalization kinetics revealed a significantly increased cellular uptake of 68Ga-10 in LNCaP cells. An increased internalization was also observed for 68Ga- and 177Lu-11 compared to radiolabeled 10 and PSMA I&T. Unlike that reported for radiolabeled DOTAGA-flk(Sub-KuE) and PSMA I&T [17, 22],

### Table 2 Cell binding and internalization of 68Ga-177Lu-10 and 68Ga-177Lu-11 compared to the reference ligands 68Ga/177Lu-PSMA I&T after 1 h on LNCaP cells (125,000/well, DMEM/T-12 + 5% BSA). Data is expressed as percentage of external reference 125I-IBA and as mean ± SD (n = 3).

| Cell binding (125I-IBA) | Internalization (125I-IBA) |
|-------------------------|---------------------------|
| 68Ga-PSMA I&T | 65.0 ± 1.7 | 59.2 ± 1.7 |
| 177Lu-PSMA I&T | 79.6 ± 1.1 | 75.5 ± 1.6 |
| 68Ga-10      | 1126 ± 2.1 | 1051 ± 2.1 |
| 177Lu-10     | 773 ± 0.7  | 717 ± 0.7  |
| 68Ga-11      | 1076 ± 1.3 | 1070 ± 1.2 |
| 177Lu-11     | 1196 ± 0.6 | 1186 ± 0.5 |
the internalization experiments do not correlate with the affinity to PSMA. Thus, the affinity and cell binding data indicate that the interaction of PSMA inhibitors 10 and 11 with PSMA differs from PSMA I&T [17, 22] and was therefore further investigated with regards to lipophilicity and in vivo behavior.

**Lipophilicity, plasma protein, and human albumin binding**

For the novel PSMA inhibitors, the partition coefficient between n-octanol and PBS (pH 7.4) was determined using the shake-flask method. The logP values (n = 6 for each) of the 68Ga- and 177Lu-labeled inhibitors 10 (−3.8 ± 0.1 and −4.1 ± 0.1 for 68Ga- and 177Lu-10, respectively) and 11 (−3.5 ± 0.1 and −3.1 ± 0.1 for 68Ga- and 177Lu-11, respectively), designed for optimized lipophilic interaction with lipophilic PSMA pockets, was correspondingly higher compared to the radiolabeled derivative PSMA I&T (−4.3 ± 0.3 and −4.1 ± 0.1 for 68Ga- and 177Lu-PSMA I&T, respectively). However, having the hydrophilic KuE motif and the chelator (DOTAGA) at both ends of the molecule, radiolabeled PSMA inhibitors 10 and 11 were still highly hydrophilic compared to other peptides, such as peptides binding the CXCR-4 receptor (logP (68Ga-CPCR4-2) = −2.90 ± 0.08) [36].

High in vivo plasma protein binding increases the plasma half-life of the radiopharmaceutical and therefore might offer beneficiary effects on the tracer distribution (higher uptake into target tissue) but can also lead to increased background activity especially at early time points [27]. In general, drugs binding to plasma proteins with high affinity feature moderate to high lipophilicity, in many cases due to halogenated aromatic groups. To estimate the bioavailability of 177Lu-PSMA I&T, 177Lu-10, and 177Lu-11 in the blood circulation, the extent of plasma protein binding was determined by in vitro incubation in human plasma and subsequent ultracentrifugation. Human albumin binding was determined, applying a modified HPLC method [37]. In accordance with an almost similar lipophilicity of 177Lu-PSMA I&T and 177Lu-10, the plasma protein binding of these PSMA inhibitors was 82% and 81%, respectively. These high values might be explained by the multiple negative charges (carboxylates of KuE and DOTAGA) at both ends of the molecules, being connected over a lipophilic peptide spacer; another structural motif reported to bind plasma proteins [31]. In addition, the intercalation of an additional iodo-phenylalanine residue increased the lipophilicity of 177Lu-11 compared to 177Lu-10. In consistency with the increased lipophilicity, the iodo-phenyl group insertion resulted in almost quantitative plasma protein binding of 97% for 177Lu-11. Similar results were obtained for the HSA binding. While natLu-PSMA I&T and natLu-10 showed values of 79% and 83% bound to HSA, the para-iodo-phenyl-substituted derivative natLu-11 exhibited 97%. The results indicate that the modification with the halogenated aromatic residue increases in first line the albumin binding, which accounts almost completely for the almost quantitative plasma protein binding of natLu-11 in vitro.

**Biodistribution**

To investigate an influence of the increased internalization of 68Ga-10 and the almost quantitative plasma protein binding of radiolabeled 11 on the in vivo behavior, the biodistribution of 68Ga-10, 68Ga-11, and PSMA I&T was determined 1 h after injection in LNCaP tumor-bearing CD-1 nu/nu mice (Fig. 3a). As expected from the highly hydrophilic tracers, their clearance was fast and exclusively via the kidneys. After 1 h, the uptake of 68Ga-labeled 11 into the tumor xenograft, the kidneys, and the spleen (all of which are organs with documented PSMA expression [38]) was comparable to 68Ga-labeled 10 and PSMA I&T. In consistency with the 97% in vitro plasma protein binding for 68Ga-11, 1.3 ± 0.1% ID/g was found in the blood after 1 h compared to 0.4 ± 0.2% ID/g for 68Ga-PSMA I&T. Interestingly, increased blood retention was also observed for 68Ga-10, although the HPLC retention, the logP, and the plasma protein binding were comparable to 68Ga-PSMA I&T. Thus, the increased internalization and elevated blood level of 68Ga-10 and 68Ga-11 compared to 68Ga-PSMA I&T merits further investigation at later time points.

With respect to a potential endoradiotherapeutic benefit of the higher blood levels of radiolabeled 10 and 11, the biodistribution of 177Lu-10 and 177Lu-11 was determined at 24 h p.i. in LNCaP tumor-bearing SCID mice (Fig. 3b). The 24-h p.i. biodistribution of 177Lu-10 revealed washout from all organs and a tumor retention (4.5 ± 1.1% ID/g), which is comparable to 177Lu-PSMA I&T (4.1 ± 1.1% ID/g). A fourfold increase of the activity in the LNCaP tumor xenograft at 24 h p.i. was observed for 177Lu-11 with 16.1 ± 2.5% ID/g. The high 177Lu-11 retention in the tumor xenograft is explained by 97% plasma protein binding, which decelerates the excretion and thus increases the uptake in PSMA-specific tissues with time. This hypothesis is supported by the higher blood activity of radiolabeled 11 compared to PSMA I&T at 1 h p.i., which might allow subsequent delivery of the PSMA inhibitor to the tumor over time. However, although the initial blood activity at 1 h p.i. of 68Ga-10 and 68Ga-11 was similar, 177Lu-10 did not show the same effect of increased tumor uptake at 24 h p.i. The data suggest that the initial distribution of both ligands is not significantly influenced by the HSA binding; however, its effect becomes more apparent at later time points. The initial α-phase of the blood clearance is dominated by especially the distribution process for
Fig. 3 Biodistribution data. 

**a** Biodistribution of 13.4 ± 0.8 MBq (approximately 0.2 nmol) $^{68}$Ga-10 and $^{68}$Ga-11 in comparison to $^{68}$Ga-PSMA I&T at 1 h p.i. in LNCaP tumor-bearing CD-1 nu/nu mice ($n = 4$, respectively). 

**b** Biodistribution and **c** tumor-to-organ ratios of the respective $^{177}$Lu-labeled compounds at 24 h p.i. in LNCaP tumor-bearing SCID mice. Data are expressed as mean ± SD ($n = 4$ or $5$).
strong and weak plasma protein binding small molecules and leads to a rapid decline of blood pool activity after i.v. injection. However, the difference in the clearance kinetics becomes more visible in the terminal elimination phase. The terminal phase is stronger dominated by elimination processes and influenced by the plasma protein binding properties of the molecule. The $^{177}$Lu-11 activity in the spleen ($6.6 \pm 3.3\%$ ID/g) and the kidneys ($100.9 \pm 45.4\%$ ID/g) was also higher for $^{177}$Lu-11 compared to $^{177}$Lu-10, confirming the effect of higher plasma protein binding on PSMA-expressing tissue uptake, PSMA-specific uptake in these organs. Similar results were observed by other groups, in which the strong albumin-binding ligands exhibited increased tumor accumulation and stronger retention [26, 27, 39]. Kelly et al. suggested that differences in kidney uptake are mediated by albumin binding and that strong binding ligands should display lower renal accumulation. This is, however, in contrary to our observation. Kidney uptake of $^{177}$Lu-11 was the highest after 24 h among the tested ligands and resembled more the results of Choy et al. [27].

Although an almost fourfold higher uptake of $^{177}$Lu-11 compared to $^{177}$Lu-10 and $^{177}$Lu-PSMA I&T was found at 24 h p.i., the tumor-to-organ ratios (Fig. 3c) of $^{177}$Lu-PSMA I&T were comparable or higher than that for $^{177}$Lu-11. The high and persistent tumor uptake of $^{177}$Lu-11 was caused by a decelerated blood clearance and probably higher metabolic stability due to stronger interactions with albumin and the resulting decreased steric accessibility of metabolizing enzymes towards the PSMA ligand. The increased tumor uptake led to high tumor-to-organ ratios at 24 h p.i., e.g., 326 ± 0.3 (tumor-to-blood) or 143 ± 0.3 (tumor-to-bone). Thus, endoradiotherapeutic application of $^{177}$Lu-11 might deliver higher radiation doses to the target tissue compared to $^{177}$Lu-PSMA I&T and $^{177}$Lu-10. However, the likewise increased blood level and especially the kidney and spleen uptake of $^{177}$Lu-11 after 24 h p.i. (Fig. 3b) most likely limits the maximal dose and has to be considered in terms of potential nephro- or hematotoxicity [40]. First-in-man studies are necessary to address the issue if the renal uptake in preclinical studies is a predictive parameter to assess the nephrotoxicity in men. The difference of preclinical results regarding the renal uptake of PSMA I&T (high) and PSMA-617 (low) and the almost identical uptake in clinical studies suggest that the kidney uptake in mice has only limited predictive value [21].

**PET imaging**

Figure 4a shows PET images of LNCaP tumor-bearing mice 1 h after injection of $^{68}$Ga-10 and $^{68}$Ga-11, respectively. In accordance with the biodistribution data, both tracers were primarily taken up into the tumor and the kidneys, with excretion into the bladder. The PSMA specificity of in vivo binding was confirmed by co-injection of the structurally independent PSMA inhibitor PMPA. In the $^{68}$Ga-11 time-activity curves of a 1.5-h observation period (Fig. 4c), the plasma protein bound activity seems to be stronger delivered to PSMA-specific organs compared to $^{68}$Ga-10 (Fig. 4b) and therefore leads to an increase in tumor uptake over time, which is consistent with the biodistribution data of $^{177}$Lu-11 at 24 h p.i.

**Conclusions**

An improved interaction of the PSMA inhibitors with the arene-binding pocket by means of the introduction of bulky and lipophilic bicyclic aromatic side chains in the linker unit resulted in higher affinity and slightly higher internalization in vitro. The delayed excretion kinetics of $^{177}$Lu-11 compared to $^{177}$Lu-10 and $^{177}$Lu-PSMA I&T, caused by 97% plasma protein binding of $^{177}$Lu-11, led to a significantly improved tumor uptake at 24 h p.i. However, in the context of the new generation of high plasma protein binding PSMA inhibitors with improved tumor uptake, first-in-man studies have to prove if an increased diagnostic, therapeutic, or theranostic value exists and if high plasma protein binding is the next big step in PSMA drug development.

**Methods**

The general experimental procedures are described in detail in Additional file 1.

**Synthetic procedures**

The PSMA inhibitors 1–9 were synthesized according to previously published methods [22, 41] with minor modifications as described in Additional file 1. For amino acid nomenclature, the one-letter code according to IUPAC-IUB was used.

**PSMA inhibitor 10**

To a solution of 2.0 g (11.5 mmol, 1.0 eq.) suberic acid in 30 mL tetrahydrofuran (THF), 2.8 mL (34.5 mmol, 3.0 eq.) pyridine, 7.1 mL (46.0 mmol, 4.0 eq.) N,N'-disopropylcarbodiimide (DIC) in 15 mL THF, and 8.47 g (46.0 mmol, 4.0 eq.) pentafluorophenol in 15 mL THF were successively added. The progress of the active ester formation was monitored using TLC (ethyl acetate/petroleum ether (55–65 °C) (1:9)). After approximately 2 h at rt, the reaction mixture was filtered, and the solvent was evaporated in vacuo. The crude product was purified via silica gel flash chromatography using an eluent mixture of ethyl acetate/petroleum ether (55–65 °C) (1:9/1). Di-pentafluorophenyl suberate (Sub(OPfp)$_2$) was obtained as a yellow crystalline solid. Calculated monoisotopic mass for Sub(OPfp)$_2$ (C$_{20}$H$_{12}$O$_4$F$_{10}$) = 506.1 (product is not detectable using ESI-MS).

To a solution of 400 mg (0.8 mmol, 1.0 eq.) (OtBu)-KuE(OtBu)$_2$ in 100 mL THF, 274 μL (1.6 mmol, 2.0 eq.)
DIPEA was added. This solution was added dropwise (within 30 min) to a solution of 1.6 g (3.2 mmol, 4.0 eq.) Sub(OPfp)2. After stirring for an additional 2 h at rt, the reaction mixture was concentrated in vacuo, and the crude product was purified via silica gel flash chromatography using a stepwise gradient of ethyl acetate in petrol-ether (55–65 °C) of 10%, 50%, 90%, and pure ethyl acetate (200 mL each). OPfp-Sub-(OTBu)KuE(OTBu)2 was obtained as a yellowish oil in 58% yield. Calculated monoisotopic mass (C38H56F5N3O10) = 809.4 found m/z = 810.6 [M + H]+, 832.4 [M + Na]+.

Peptide synthesis of y-nal-k and DOTAGA coupling to the deprotected N-terminus of the peptide was performed as described previously [22]. DOTAGA-tyrosine-2-naphthylalanine-lysine HPLC (20 to 70% B in 15 min) found tR = 10.7 min, K’ = 4.1. Calculated monoisotopic mass (C47H64N8O14) = 964.5 found m/z = 965.8 [M + H]+, 987.8 [M + Na]+.

Reaction conditions of the peptide with OPfp-Sub-(OTBu)KuE(OTBu)2 were similar as described for the respective NHS ester. DOTAGA-γ-2-nal-k(Sub-KuE) (10) HPLC (25 to 55% B in 15 min.) found tR = 12.5 min, K’ = 6.14. Calculated monoisotopic mass (C67H95N11O23) = 1421.7 found m/z = 1422.8 [M + H]+, 1444.9 [M + 2H]2+.

**PSMA inhibitor 11**

To a solution of 2.0 g (15.1 mmol, 1.0 eq.) glutaric acid in 15 mL, THF was added 3.7 mL (45.4 mmol, 3.0 eq.) pyridine, 9.5 mL (60.5 mmol, 4.0 eq.) DIC in 10 mL THF, and 11.1 g (60.5 mmol, 4.0 eq.) pentafluorophenol in 10 mL THF. After 2 h, the solvent was removed in vacuo, and the crude dissolved in petrol ether was filtered and purified using silica gel flash chromatography (petrol ether/ethyl acetate = 95/5) yielding 6.1 g (87%) di-pentafluorophenyl glutarate (Glut(OPfp)2) as a white crystalline solid. HPLC (10 to 100% B in 15 min) found tR = 17.5 min, K’ = 7.75. Calculated monoisotopic mass (C19H36N4O6) = 416.3 found m/z = 417.1 [M + H]+.

A solution of 0.5 g (0.97 mmol, 1.2 eq.) Fmoc-D-4-iodo-phenylalanine, 0.2 g (1.22 mmol, 1.5 eq.) HOAt,
0.2 mL (0.16 g, 1.22 mmol, 1.5 eq.) DIC, and 0.6 mL (0.47 g, 3.65 mmol, 4.5 eq.) DIPEA in 15 mL THF was stirred at rt. for 1 h. After the addition of 395 mg (0.81 mmol, 1.0 eq.) (OrBu)KuE(OrBu)₂ in 5 mL THF, the reaction mixture was stirred overnight. Water (20 mL) was added and extracted with 25 mL ethyl acetate (3x), followed by 20 mL H₂O (3x) and 25 mL brine. The organic phase was dried over MgSO₄, and the solvent was evaporated in vacuo yielding 2.0 g (>100%) Fmoc-(I-f)-(OrBu)KuE(OrBu)₂ as a white solid, which was dissolved in 25.0 mL DMF, and 5.0 mL piperidine was added and stirred for 2 h. The crude product was purified using HPLC (58% B isocratic). HPLC (10 to 90%) found tR = 15.6 min, K’ = 8.2. Calculated monoisotopic mass (C₃₃H₅₃IN₄O₈) 760.3 found m/z = 761.4 [M + H]⁺, 783.4 [M + Na]⁺, 799.4 [M + K]⁺, 593.3 [M-3 tBu + H]⁺, 649.3 [M-2 tBu + H]⁺, 705.3 [M- tBu + H]⁺. 

At 0 °C, 270 mg (0.021 mmol, 1.0 eq.) (I-f)-(OrBu)-KuE(OrBu)₂ and 122 μL (0.71 mmol, 2.0 eq.) DIPEA in 20 mL THF were slowly added to 660 mg (1.42 mmol, 1.0 eq.) Glut(OPfp)₂ dissolved in 10 mL THF. After 2 h at rt., the solvent was removed in vacuo, and the crude product was purified using silica gel flash chromatography (petrol ether/ethyl acetate 10/1) yielding 143 mg (0.81 mmol, 1.0 eq.) (O

For lipophilicity determination, samples of 1–2 MBq ⁶⁸Ga/¹⁷⁷Lu-10 or ⁶⁸Ga/¹⁷⁷Lu-11 in 500 μL PBS, respectively, were added to 500 μL n-octanol (n = 6), mixed gently for 3 min, and centrifuged for 3 min. A 100-μL octanol and a 50-μL PBS sample were quantified using a γ-counter, respectively.

Plasma protein binding was determined in fresh blood samples collected in heparinized tubes, which were centrifuged at 6000 rpm (Biofuge 15, Heraeus Sepatech, Osterode, Germany) to separate plasma from the blood cells. Subsequently, 1–2 MBq ¹⁷⁷Lu-10 or ¹⁷⁷Lu-11 was added to the fresh plasma, respectively, and was incubated at 37 °C for 15 min. The sample was transferred into a VWR 30K (low protein binding) modified PES ultrafiltration vial and centrifuged at 16000 rpm. Quantification of the activity concentration before and after ultrafiltration was performed in a γ-counter. The data was corrected for non-specific association to the membrane (ultrafiltration of tracer sample in PBS).

HSA binding experiments were performed according to a previously reported method using a binary gradient HPLC system connected to a Chiralpak HSA (5 μm, 50 x 3 mm) analytical column connected to a Chiralpak HSA (5 μm, 10 x 3 mm) guard cartridge (Daicel Chemical Industries) purchased from Chiral Technologies Europe (Illkirch, France) with minor modifications [37]. Mobile phase A was an ammonium acetate buffer (50 mM, pH 6.9), mobile phase B was 2-propanol, the flow rate was 0.5 mL/min, and equilibration with 0% B for 3 min was followed by a gradient of 0% B to 20% B to the end of each run within 45 min. To check the column performance and to conduct the non-linear regression, the HSA column was calibrated each day with nine reference substances. Afterward, the PSMA inhibitors with unknown HSA binding were measured. The retention times and factors together with correlation curve are found in Additional file 1.

**In vitro evaluation**

Experimental details for the determination of the affinity to PSMA (IC₅₀), the cell binding and internalization kinetics, and the specificity of binding in vitro were described previously [17, 22] and are summarized in Additional file 1.

**Biodistribution and PET imaging**

All animal experiments were conducted in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval number 55.2.1-54-2532-71-13). Tumor induction and experimental details were described previously [17, 22] and are summarized in Additional file 1.
Acknowledgements
The synthetic contribution of Sophia Beslmüller and Stefanie Heilmann is highly acknowledged. We thank Sybille Reder, Markus Mittelhäuser, and Marco Lehmann for small-animal imaging.

Funding
M.Schw has received funding from the European Union Seventh Framework Program (FP7) under Grant Agreement No. 294582 ERC Grant MUMI. The development of the PSMA inhibitors was supported by SFB 824 (DFG Sonderforschungsbereich 824, Project Z1) from the Deutsche Forschungsgemeinschaft, Bonn, Germany.

Availability of data and materials
All animal experiments were conducted in accordance with the German Ethics approval and the final manuscript. SR and TG were supported the preclinical evaluation of the PSMA inhibitors and in revising the manuscript. AS was involved in the in vitro and in vivo evaluation, performed the data interpretation and in revising the manuscript. MW carried out the design and synthesis of the PSMA ligands, performed in the data interpretation and in revising the manuscript. SR and TG were involved in the in vivo evaluation and revised the final manuscript. M.Schw supported the preclinical evaluation of the PSMA inhibitors and in revising the final manuscript. HJW initiated the development and evaluation of the lipophilic PSMA inhibitors and participated in the data interpretation and in writing the manuscript and revising the final manuscript. All authors read and approved the final manuscript.

Ethics approval
All animal experiments were conducted in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval 55.2-1-54-2532-71-13).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany. 2Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Received: 30 May 2018 Accepted: 14 August 2018
Published online: 22 August 2018

References
1. Silver DA, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.
2. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39.
3. Rawlings ND, Barrett AJ. Structure of membrane glutamate carboxypeptidase. Biochim Biophys Acta. 1997;1339(2):247–52.
4. Kozikowski AP, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem. 2004;47(7):1729–38.
5. Afshar-Oromieh A, et al. The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.
6. Benešová M, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914–20.
7. Robu S, et al. Preclinical evaluation and first patient application of 99mTc-PSMA-i65 for SPECT imaging and radioguided surgery in prostate cancer. J Nucl Med. 2017;58(2):235–242.
8. Weineisen M, et al. Development and first in human evaluation of PSMA &t-A ligand for diagnostic imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2014;55(supplement 1):1083.
9. Szabo Z, et al. Initial evaluation of [18 F] DCPyl for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565–74.
10. Schmidt A, et al. Effect of Carbohydration on the Theranostic Tracer PSMA &t-ACS omega. 2018;3(7):8278–8287.
11. Bander NR, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003;170(5):1717–21.
12. Robu S, et al. Synthesis and preclinical evaluation of novel 18 F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with 18 F-DCPyl and 18 F-PSMA-1007. EJNMMI Res. 2018;8(1):30.
13. Zhang AX, et al. A remote urea-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2016;138(12):7271–6.
14. Eder M, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688–97.
15. Afshar-Oromieh A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(11):1–20.
16. Eiber M, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):686–74.
17. Weineisen M, et al. 68Ga- and 177Lu-labeled PSMA &t-optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015;56(8):1169–76.
18. Herrmann A, et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy. J Nucl Med. 2015;56(8):855–61.
19. Kulkarni H, et al. Therapy of metastasized castrate-resistant prostate cancer using Lu-177 labeled DOTAGA-PSMA small molecules: first clinical results in a larger patient cohort. J Nucl Med. 2015;56(supplement 3):10.
20. Baum RP, et al. Lutetium-177 PSMA radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–1013.
21. Kulkarni HR, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the Bad Berka experience since 2013. J Nucl Med. 2016;57(supplement 3):975–1045.
22. Weineisen M, et al. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(1):63.
23. Maurer T, et al. Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. Eur J Nucl Med. 2015;42(3):530–4.
24. Schottelius M, et al. [111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015;5:68.
25. Mareska KP, et al. A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer. J Med Chem. 2009;52(2):347–57.
26. Kelly JM, et al. Dual-target binding ligands with modulated pharmacokinetics for endoradiotherapy of prostate cancer. Journal of Nuclear Medicine. 2017; p. e11. 116.188722.
27. Choy CJ, et al. 177Lu-labeled phosphoramidate-based PSMA inhibitors: the effect of an albumin binder on biodistribution and therapeutic efficacy in prostate tumor-bearing mice. Theranostics. 2017;7(7):1929.
28. Benesova M, et al. Linker modifications of DOTA-conjugated inhibitors of the prostate-specific membrane antigen (PSMA). Eur J Nucl Med Mol Imaging. 2013;40:5281.
29. Durnelin CE, et al. A portable albumin binder from a DNA-encoded chemical library. Angew Chem Int Ed Engl. 2008;47(17):3196–201.
30. Hiller SM, et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res. 2009;69(17):6932–40.
31. Kratochwil NA, et al. Predicting plasma protein binding of drugs: a new approach. Biochem Pharmacol. 2002;64(9):1355–74.
32. Barinka C, et al. Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. J Med Chem. 2008;51(24):7737–43.
33. Barinka C, et al. A high-resolution structure of ligand-free human glutamate carboxypeptidase II. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63(Pt 3):150–3.
34. Benešová M, et al. Linker modification strategies to control the prostate-specific membrane antigen (PSMA)-targeting and pharmacokinetic properties of DOTA-conjugated PSMA inhibitors. J Med Chem. 2016;59(5):1761–75.
35. Wang H, et al. Bioisosterism of urea-based GCPII inhibitors: synthesis and structure–activity relationship studies. Bioorg Med Chem Lett. 2010;20(1):392–7.
36. Gourni E, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52(11):1803–10.
37. Valko K, et al. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J Pharm Sci. 2003;92(11):2236–48.
38. Bacich DJ, et al. Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome. 2001;12(2):117–23.
39. Benešová M, et al. Albumin-binding PSMA ligands: optimization of the tissue distribution profile. Molecular pharmaceutics. 2018;15(2):934-946.
40. Rathke H, et al. Dose escalation of 177Lu-PSMA-617 from 4 to 9.3 GBq per cycle in patients with mCRPC. J Nucl Med. 2017;58(supplement 1):313.
41. Schottelius M, et al. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radiiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J Med Chem. 2005;48(8):2778–89.